Asymptomatic herpes simplex type 1 virus infection of the mouse brain.

An asymptomatic and transitory brain infection takes place in adult Swiss CD-1 mice after intranasal inoculation of HSV-1 strain SC16. Time course and distribution of the infection in the brain are demonstrated, (i) by titration of the nasal tissue and olfactory bulbs for 16 days post-infection (p.i.), showing a maximum production yield on day 7 p.i. and no replicating virus on day 16 p. i.; (ii) expression in the brain of the lac Z reporter gene of HSV-1 strain SC16-DeltaUS5-lac Z consistent with a central spread of the virus through the central olfactory pathways and the trigeminal system as described in acute HSV-1 encephalitis models; (iii) PCR amplifications of a segment of the thymidine kinase gene (HSV-tk) showing the persistence of viral genome in the nasal tissue and olfactory bulbs after clearance of infectious virus. The asymptomatic character of the infection is demonstrated over 2 months p.i. (i) by normal body weight; (ii) a neurological survey which excludes motor, sensory, balance and postural signs; (iii) two behavioral tests, the open-field test for exploratory activity and the cookie-finding test for olfactory search. On the other hand, intracerebral inocula cause encephalitis and death in a few days (LD50 ca. 14 p.f.u.). Intracranial, surgical transection of one olfactory nerve does not prevent infection of the corresponding bulb nor does it modify virus distribution, suggesting multiple entry routes from the nasal cavity to the brain. In conclusion, HSV-1 strain SC16 reaches the brain of CD-1 mice from the nasal cavity and replicates without neurological or behavioral signs.

Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans.

Retrovirus-mediated gene therapy is a particularly attractive approach for glioblastoma multiforme (GBM), given the poor prognosis of this tumour and its localized proliferation in post-mitotic tissue. In this study we assessed, for the first time in humans, the therapeutic potential of a newly designed bicistronic Moloney vector (pLIL-2-TK), combining the expression of a suicide gene (thymidine kinase, tk) with an immunomodulatory gene (human interleukin 2, IL-2). Evidence of transgene activity in the treated tumours is presented.

Herpes simplex virus chronically infected human T lymphocytes are susceptible to HIV-1 superinfection and support HIV-1 pseudotyping.

Peripheral blood lymphocytes (PBL) and CEM CD4+ T-cell line can be infected by herpes simplex virus-1 (HSV-1). CEM cells were characterized as a cellular model to study interactions occurring between HSV-1 and HIV-1. Virtually all cells were persistently infected by HSV-1 (CEM(HSV)) and expressed the latency associated transcripts, whereas only a fraction tested positive for HSV-antigens. CD4 and CXCR-4 expression and function were not affected in CEM(HSV) cells and no significant increase of deoxyribonucleotide pools was noticed. Superinfection of CEM(HSV) cells with HIV-1 led to a cell line chronically infected by both viruses (CEM(HSV/HSV)). Evidence was also obtained that this cell line can produce HIV-1 pseudotyped by HSV-1 envelope. These results may have important implications for a better understanding of AIDS pathogenesis.

Production and characterization of a bicistronic Moloney-based retroviral vector expressing human interleukin 2 and herpes simplex virus thymidine kinase for gene therapy of cancer.

Gene-based therapeutic strategies for cancer mainly include augmentation of immunotherapeutic and chemotherapeutic approaches. In this study we report the design and functional assay of a novel bicistronic Moloney-based retroviral vector expressing human interleukin-2 (IL-2) and herpesvirus thymidine kinase (tk) through a cap-dependent translation and an internal ribosome entry site (IRES)-regulated translation, respectively. This construct has the potential for allowing combination of cytokine and suicide gene therapy, especially in areas such as the brain, composed of post-mitotic cells refractory to transduction by type C retroviral vectors. Accordingly, human glioma cells were used as targets for gene transfer after selecting a packaging cell clone that produced a reasonable titer of recombinant virus and expressed high levels of IL-2 and tk transcripts. Although transduction efficiency was reduced in glioma cells as compared with murine NIH 3T3 cells, transgene expression was effectively achieved. Transduced glioma cells were sensitive to ganciclovir and secreted around 1000 U/ml IL-2 in the culture supernatants. Simultaneous production of IL-2 and tk in vivo by genetically treated tumor cells would hopefully potentiate the effect of gangiclovir-induced metabolic suicide, possibly by boosting the immune response associated with tumor debulking or by amplifying the bystander response.

Gene stereotactic neurosurgery for recurrent malignant gliomas.

Four patients affected by glioblastoma recurrence were treated with a gene therapy-immunotherapy protocol consisting of intratumoral injections of culture cells producing a retroviral vector which expresses human interleukin-2 and the herpes simplex virus thymidine kinase genes. Seven to 14 days after implantation, the patients were treated with ganciclovir at standard doses. Anatomopathological and immunohistochemical data confirm the efficacy of transduction. From the clinical point of view, gene therapy combined with immunotherapy demonstrated safety and a short-range but clearcut oncolytic effect.

Cytogenetic analysis of transitional cell carcinoma of the bladder. Clinical implications.

Cytogenetic analysis of resected bladder tumors was performed in 30 patients. None of these patients had previous irradiation or chemotherapy. Direct chromosome preparations were made. Of the 30 preparations, 20 had chromosome abnormalities. We have observed a good correlation between the chromosome abnormalities and the stage/grade of the tumors. Patients were followed from 3 to 23 months. During this period, 61% of the patients with noninvasive or submucosal invasive bladder tumors and chromosome abnormalities have had recurrences. The existence of a good correlation between chromosomal abnormalities and the capacity of the neoplasm to recur was confirmed.